Clinical Trials Browser

Hepatitis C × pembrolizumab × Gastrointestinal × Clear all

NCT02940496 2025-07-15

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

Phase 2 Completed

15 enrolled 8 charts

Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular